SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice

被引：0
|
作者：
John Wilding
Kevin Fernando
Nicola Milne
Marc Evans
Amar Ali
Steve Bain
Debbie Hicks
June James
Philip Newland-Jones
Dipesh Patel
Adie Viljoen
机构：
[1] University of Liverpool,Obesity and Endocrinology Research
[2] North Berwick Health Centre,Department of Diabetes
[3] CODES (COmmunity Diabetes Education and Support),Diabetes Research Unit Cymru
[4] University Hospital Llandough,Department of Diabetes and Endocrinology
[5] Oakenhurst Medical Practice,Department of Metabolic Medicine/Chemical Pathology
[6] Swansea University,undefined
[7] Barnet,undefined
[8] Enfield and Haringey Mental Health Trust,undefined
[9] University Hospitals of Leicester NHS Trust,undefined
[10] University Hospitals Southampton NHS Foundation Trust,undefined
[11] Royal Free NHS Foundation Trust,undefined
[12] Lister Hospital,undefined
来源：
Diabetes Therapy | 2018年 / 9卷
关键词：
Clinical guidance; Glucose-lowering medicines; Oral glucose-lowering medicines; Prescribing tools; Risk/benefit; SGLT2 inhibitors; Therapy choice; Type 2 diabetes;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1757 / 1773
页数：16
相关论文
共 50 条
  • [31] Practical Approach to Initiating SGLT2 Inhibitors in Type 2 Diabetes
    Gomez-Peralta, Fernando
    Abreu, Cristina
    Lecube, Albert
    Bellido, Diego
    Soto, Alfonso
    Morales, Cristobal
    Brito-Sanfiel, Miguel
    Umpierrez, Guillermo
    DIABETES THERAPY, 2017, 8 (05) : 953 - 962
  • [32] Role of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus
    Solini, Anna
    ACTA DIABETOLOGICA, 2016, 53 (06) : 863 - 870
  • [33] SGLT2 inhibitors: providing cardiovascular protection in type 2 diabetes?
    Wilding, John
    LANCET DIABETES & ENDOCRINOLOGY, 2016, 4 (05): : 379 - 381
  • [34] SGLT2 inhibitors in type 2 diabetes: an audit of early experience
    Cooke, B.
    Ryan, K.
    Gormley, M.
    Lindsay, J. R.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2014, 183 : S455 - S455
  • [35] Are SGLT2 inhibitors joining the mainstream therapy for diabetes type 2?
    Hassanabad, Mortaza E.
    Abad, Zahra F. H.
    DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2019, 13 (03) : 1893 - 1896
  • [36] The effects of SGLT2 inhibitors on corneal neuroinflammation in type 2 diabetes
    Asiedu, Kofi
    Tummanapalli, Shyam
    Alotaibi, Sultan
    Wang, Leiao Leon
    Dhanapalaratman, Roshan
    Kwai, Natalie
    Poynten, Ann
    Krishnan, Arun
    Markoulli, Maria
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)
  • [37] Role of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus
    Anna Solini
    Acta Diabetologica, 2016, 53 : 863 - 870
  • [38] SGLT2 inhibitors in diabetes with CKD
    Malik, A. H.
    Yandrapalli, S.
    Goldberg, M.
    Jain, D.
    Frishman, W. H.
    Aronow, W. S.
    EUROPEAN HEART JOURNAL, 2019, 40 : 1448 - 1448
  • [39] Cardiorenal Protections of SGLT2 Inhibitors in the Treatment of Type 2 Diabetes
    Nazari, Somayeh
    Mirkhani, Hossein
    CURRENT DIABETES REVIEWS, 2023, 19 (08)
  • [40] SGLT2 inhibitors and autophagy in diabetes
    Yaribeygi, Habib
    Maleki, Mina
    Atkin, Stephen L.
    Jamialahmadi, Tannaz
    Sahebkar, Amirhossein
    CELL BIOCHEMISTRY AND FUNCTION, 2023, 41 (04) : 392 - 398
12345